A deal's done: Less than a month after receiving Novartis' stall of vaccines products, GlaxoSmithKline has ended the yearlong pricing standoff with the United Kingdom's National Health Service over meningitis B vaccine Bexsero.
In a $31 million development agreement with Emergent BioSolutions announced Monday, the Department of Health and Human Services said it will fund Phase III development for NuThrax, Emergent's new anthrax vaccine that's already been funded through Phase I and II by the NIH and the Department of Defense.
BCG (Bacille Calmette-Guérin) is the only WHO-approved tuberculosis vaccine and is given to infants, but has proven ineffective in adults. Enter GlaxoSmithKline, which, along with Aeras and Kenya Medical Research Institute, will roll their candidate in Phase IIb trials in Kenya.
Sanofi Pasteur counts pediatric vaccines among its 5 key areas, and it's bolstering its offerings in the field with Wednesday's FDA approval of the Quadracel vaccine.
Results from the Phase I trial of yet another experimental Ebola vaccine are in, but unlike other vaccines in the field, this one is based on the virus strain that caused the 2014 epidemic, and not an older one. The vaccine, developed by Beijing Institute of Biotechnology and Tianjin CanSino Biotechnology, is called a recombinant adenovirus type-5 vaccine.
In January, Germany's cost watchdog decided that Dendreon's--now Valeant's--Provenge had no added benefit for men with metastatic prostate cancer. But now, it's changing its tune.
It's been 7 months since price negotiations over meningitis B vaccine Bexsero began between Novartis and the U.K. government. And as far as new owner GlaxoSmithKline is concerned, that's long enough.
Aduro Biotech is the latest to try its hand at an IPO, and it laid out its case for an $86 million IPO last week.
After a damaging delay back in 2007, Worthing, U.K.-based Allergy Therapeutics is attempting to revive its Pollinex Quattro Grass allergy vaccine. And now, it has some new funding to help it do just that.
GlaxoSmithKline is testing its Ebola jab in Africa to see if it provokes an immune response strong enough to successfully beat an Ebola infection. But if it turns out to be too weak, never fear--the Big Pharma has a plan. It's teaming up with Maryland-based Emergent BioSolutions to test the latter's Ebola shot as a booster for its own vaccine.
After rolling out its long-delayed Shan5 vaccine in November, Sanofi's Indian affiliate, Shantha Biotechnics, is ready to provide up to 37 million doses, having already started the process on Tuesday.
England has decided to offer meningitis W vaccination to three million teens after a steep rise in cases--and local vaccine giant GlaxoSmithKline will be reaping the benefits.
Over the past year, Pfizer has certainly achieved CEO Ian Read's goal of bulking up beyond best-selling vaccine Prevnar 13. In addition to ushering its meningitis B vaccine through the clinic to an FDA approval, it's made two pickups to expand its marketed portfolio and pipeline. So what's next for the pharma giant's vaccines unit? Perhaps more deals, its leader says.
Diabetes vaccine developer Diamyd Medical is running a Phase II test to see if its candidate, Diamyd, can prevent or delay the onset of Type 1 diabetes in children at very high risk of presenting with the disease.
The number of Ebola cases in West Africa has been declining, which has made it more difficult to enroll patients for clinical trials of leading vaccine candidates. And the way GlobalData analyst Daian Cheng sees it, that means it's time for vaccine manufacturers to "weigh the risks and benefits of developing further interventions for a disease that goes through unpredictable cycles of intense outbreaks followed by its virtual disappearance."
After a four-year drought, Bavarian Nordic has finally had its first full year of profit. The company announced Wednesday that it had a full-year net profit of 25.9 Danish kroner ($3.72 million) and that it expects 1.1 billion kroner ($159 million) in revenue for 2015.
The Bill & Melinda Gates Foundation announced this week it's betting on CureVac, a move both Sanofi and Boehringer Ingelheim made last year, committing to an mRNA technology designed to make vaccines less expensive and easier to make.
Takeda has been singing a globalization mantra when it comes to its vaccines unit, and that's already led it to dump one R&D program as it zeroes in on "higher impact" public health endeavors. Now, it's bowing out of another vaccine program--this time for HPV.
Back in 2011, Indian company Bharat Biotech pledged to offer its rotavirus prospect at a price that undercut even discounted vaccines from GlaxoSmithKline and Merck. Now, it's ready to make good on its promise.
After a handful of large-scale monotherapy flops for cancer vaccines, many companies now think pairing them up as part of immunotherapy combos might be the way to go. And immuno-oncology pioneer Bristol-Myers Squibb just made a big bet that that's the case.